Market Overview

UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside

Related LLY
US Stock Futures Down; JPMorgan Earnings In Focus
Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration, no terms
Lilly (LLY) Halts CETP Inhibitor Development, Shares Tumble (Zacks)

Citigroup maintained Eli Lilly and Company (NYSE: LLY) with a Buy rating and raised the price target from $55.00 to $60.00.

Citigroup noted, "Lilly's base business is performing ahead of our expectations (Alimta, Elanco, Diabetes and Emerging markets). Consequently, we continue to see upside for Lilly due to the asymmetric risk reward given the minimal value being discounted for the key pipeline agent ramucirumab (cancer). Buy-rated Pfizer, Lilly and Forest remain our favoured names in US pharma."

Eli Lilly closed at $54.32 on Tuesday.

Latest Ratings for LLY

Oct 2015Leerink SwannMaintainsOutperform
Oct 2015Credit SuisseUpgradesNeutralOutperform
Sep 2015JP MorganMaintainsNeutral

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings


Related Articles (LLY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters